Willis Investment Counsel Boosts Position in The Clorox Company $CLX

Willis Investment Counsel boosted its position in shares of The Clorox Company (NYSE:CLX) by 4.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 232,400 shares of the company’s stock after purchasing an additional 9,494 shares during the period. Clorox makes up 1.6% of Willis Investment Counsel’s holdings, making the stock its 22nd biggest holding. Willis Investment Counsel owned 0.19% of Clorox worth $28,655,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in CLX. Total Investment Management Inc. purchased a new position in shares of Clorox during the 2nd quarter worth $25,000. NewSquare Capital LLC boosted its stake in Clorox by 567.6% during the second quarter. NewSquare Capital LLC now owns 227 shares of the company’s stock worth $27,000 after buying an additional 193 shares during the period. True Wealth Design LLC increased its position in shares of Clorox by 1,020.0% during the third quarter. True Wealth Design LLC now owns 224 shares of the company’s stock valued at $28,000 after acquiring an additional 204 shares during the last quarter. Darwin Wealth Management LLC acquired a new stake in shares of Clorox during the second quarter valued at about $29,000. Finally, Root Financial Partners LLC purchased a new stake in shares of Clorox in the 3rd quarter valued at approximately $29,000. Hedge funds and other institutional investors own 78.53% of the company’s stock.

Clorox Stock Down 0.4%

Shares of NYSE CLX opened at $117.18 on Friday. The company has a quick ratio of 0.50, a current ratio of 0.74 and a debt-to-equity ratio of 71.03. The Clorox Company has a 52-week low of $96.66 and a 52-week high of $159.04. The business has a 50-day moving average price of $105.58 and a 200 day moving average price of $114.01. The stock has a market cap of $14.17 billion, a PE ratio of 19.18, a price-to-earnings-growth ratio of 0.57 and a beta of 0.59.

Clorox (NYSE:CLX) last released its quarterly earnings results on Tuesday, February 3rd. The company reported $1.39 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.04). Clorox had a return on equity of 383.01% and a net margin of 11.17%.The company had revenue of $1.67 billion for the quarter, compared to analysts’ expectations of $1.64 billion. During the same period in the prior year, the business earned $1.55 EPS. The business’s quarterly revenue was down .8% compared to the same quarter last year. Equities research analysts forecast that The Clorox Company will post 7.15 earnings per share for the current year.

Clorox Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Wednesday, January 28th will be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 4.2%. The ex-dividend date is Wednesday, January 28th. Clorox’s payout ratio is 81.05%.

Analyst Ratings Changes

CLX has been the subject of several research reports. Citigroup lifted their target price on shares of Clorox from $109.00 to $115.00 and gave the company a “neutral” rating in a report on Wednesday. UBS Group boosted their price objective on Clorox from $115.00 to $121.00 and gave the company a “neutral” rating in a report on Wednesday. Weiss Ratings lowered Clorox from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday. Wall Street Zen downgraded Clorox from a “hold” rating to a “sell” rating in a research report on Saturday, January 24th. Finally, Barclays reissued an “underweight” rating and set a $109.00 price target on shares of Clorox in a research report on Friday, January 16th. One analyst has rated the stock with a Buy rating, ten have assigned a Hold rating and five have given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Reduce” and an average target price of $117.93.

Trending Headlines about Clorox

Here are the key news stories impacting Clorox this week:

• Positive Sentiment: Morgan Stanley raised its price target to $136 and kept an “equal weight” rating, highlighting upside vs. the current share level. Clorox (NYSE:CLX) Price Target Raised to $136.00 at Morgan Stanley
• Positive Sentiment: Jefferies trimmed its target to $151 but maintained a “buy” rating, signaling continued conviction in the longer-term upside (large percentage upside remains). Jefferies Adjusts Clorox Price Target to $151
• Neutral Sentiment: Clorox will present at the CAGNY conference Feb. 19; management access may provide additional color for investors but is not an immediate earnings driver. Clorox to Present at 2026 CAGNY Conference
• Neutral Sentiment: Company is weighing a potential GOJO deal and completing an ERP integration — strategic moves that could boost long-term positioning but are creating near-term execution/cost uncertainty. Clorox Weighs GOJO Deal And ERP Finish Against Softer Earnings
• Neutral Sentiment: JPMorgan nudged its target to $117 and kept a neutral rating — a minimal change that signals little near-term conviction from that shop. JPMorgan Adjusts Clorox PT to $117
• Neutral Sentiment: TD Cowen raised its target slightly to $111 and maintained a “hold”, a modest signal relative to other shops. TD Cowen Adjusts Clorox Price Target to $111
• Negative Sentiment: Brokerage consensus across several shops shows a tilt toward downgrade/reduction in enthusiasm (a published “Reduce” consensus was flagged), which increases selling pressure. The Clorox Company (NYSE:CLX) Given Consensus Rating of “Reduce” by Brokerages
• Negative Sentiment: Q2 results were mixed: adjusted EPS missed estimates, organic sales declined year-over-year and management cited ERP/inventory pressures that are squeezing margins. Clorox Q2 Earnings Miss Estimates, Lower Organic Sales Hurt
• Negative Sentiment: Analysts warn of a near-term profit squeeze from inventory resets and integration costs, a structural headwind for margins in 2026. Clorox Faces Profit Squeeze From Inventory Reset In 2026
• Negative Sentiment: Evercore cut its target to $115 and kept an “underperform” rating, and Deutsche Bank trimmed its target to $112 — additional downward pressure from institutional sellers. Evercore Adjusts Clorox Price Target to $115

Insider Buying and Selling

In other Clorox news, Director Pierre R. Breber bought 4,000 shares of the company’s stock in a transaction on Friday, November 21st. The shares were bought at an average price of $104.13 per share, for a total transaction of $416,520.00. Following the transaction, the director owned 13,000 shares of the company’s stock, valued at approximately $1,353,690. This trade represents a 44.44% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.63% of the stock is currently owned by insiders.

About Clorox

The Clorox Company is a leading manufacturer and marketer of consumer and professional products designed to help people care for their homes and live healthy, sustainable lives. Its portfolio spans cleaning and household products, food and beverages, water filtration systems and cat litter, serving both retail and institutional customers. The company’s flagship bleach and disinfecting products are well known in the United States and many international markets, where they help prevent the spread of germs in homes, hospitals, schools and businesses.

Clorox’s diverse brand lineup includes liquid bleach and surface cleaners, eco-friendly cleaning tools, food preservation and preparation items, charcoal grills and briquettes, specialty foods and beverages, pet care products and personal care lines.